305 related articles for article (PubMed ID: 37901240)
1. Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer.
Hossain F; Ucar DA; Monticone G; Ran Y; Majumder S; Larter K; Luu H; Wyczechowska D; Heidari S; Xu K; Shanthalingam S; Matossian M; Xi Y; Burow M; Collins-Burow B; Del Valle L; Hicks C; Zabaleta J; Golde T; Osborne B; Miele L
Front Immunol; 2023; 14():1244159. PubMed ID: 37901240
[TBL] [Abstract][Full Text] [Related]
2. Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways.
Hossain F; Sorrentino C; Ucar DA; Peng Y; Matossian M; Wyczechowska D; Crabtree J; Zabaleta J; Morello S; Del Valle L; Burow M; Collins-Burow B; Pannuti A; Minter LM; Golde TE; Osborne BA; Miele L
Front Oncol; 2018; 8():575. PubMed ID: 30564555
[TBL] [Abstract][Full Text] [Related]
3. Substrate sequence influences γ-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein.
Sagi SA; Lessard CB; Winden KD; Maruyama H; Koo JC; Weggen S; Kukar TL; Golde TE; Koo EH
J Biol Chem; 2011 Nov; 286(46):39794-803. PubMed ID: 21868380
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model.
Mediratta K; El-Sahli S; Marotel M; Awan MZ; Kirkby M; Salkini A; Kurdieh R; Abdisalam S; Shrestha A; Di Censo C; Sulaiman A; McGarry S; Lavoie JR; Liu Z; Lee SH; Li X; Sciumè G; D'Costa VM; Ardolino M; Wang L
Front Immunol; 2024; 15():1366197. PubMed ID: 38601156
[TBL] [Abstract][Full Text] [Related]
5. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells.
Li ZL; Chen C; Yang Y; Wang C; Yang T; Yang X; Liu SC
Int J Clin Exp Pathol; 2015; 8(5):4378-87. PubMed ID: 26191129
[TBL] [Abstract][Full Text] [Related]
6. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
Front Immunol; 2019; 10():804. PubMed ID: 31105691
[TBL] [Abstract][Full Text] [Related]
7. More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.
López-Nieva P; González-Sánchez L; Cobos-Fernández MÁ; Córdoba R; Santos J; Fernández-Piqueras J
Oncologist; 2021 Feb; 26(2):e298-e305. PubMed ID: 33191568
[TBL] [Abstract][Full Text] [Related]
8. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
9. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.
Stoeck A; Lejnine S; Truong A; Pan L; Wang H; Zang C; Yuan J; Ware C; MacLean J; Garrett-Engele PW; Kluk M; Laskey J; Haines BB; Moskaluk C; Zawel L; Fawell S; Gilliland G; Zhang T; Kremer BE; Knoechel B; Bernstein BE; Pear WS; Liu XS; Aster JC; Sathyanarayanan S
Cancer Discov; 2014 Oct; 4(10):1154-67. PubMed ID: 25104330
[TBL] [Abstract][Full Text] [Related]
10. Effects of sulindac sulfide on the membrane architecture and the activity of gamma-secretase.
Gamerdinger M; Clement AB; Behl C
Neuropharmacology; 2008 May; 54(6):998-1005. PubMed ID: 18359496
[TBL] [Abstract][Full Text] [Related]
11. DR-5 and DLL-4 mAb Functionalized SLNs of Gamma-Secretase Inhibitors- An Approach for TNBC Treatment.
Kumari M; Krishnamurthy PT; Pinduprolu SKSS; Sola P
Adv Pharm Bull; 2021 Sep; 11(4):618-623. PubMed ID: 34888208
[TBL] [Abstract][Full Text] [Related]
12. γ-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct.
Ran Y; Hossain F; Pannuti A; Lessard CB; Ladd GZ; Jung JI; Minter LM; Osborne BA; Miele L; Golde TE
EMBO Mol Med; 2017 Jul; 9(7):950-966. PubMed ID: 28539479
[TBL] [Abstract][Full Text] [Related]
13. Second generation γ-secretase modulators exhibit different modulation of Notch β and Aβ production.
Wanngren J; Ottervald J; Parpal S; Portelius E; Strömberg K; Borgegård T; Klintenberg R; Juréus A; Blomqvist J; Blennow K; Zetterberg H; Lundkvist J; Rosqvist S; Karlström H
J Biol Chem; 2012 Sep; 287(39):32640-50. PubMed ID: 22851182
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.
Valcourt DM; Dang MN; Scully MA; Day ES
ACS Nano; 2020 Mar; 14(3):3378-3388. PubMed ID: 32083466
[TBL] [Abstract][Full Text] [Related]
15. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
Zhang S; Chung WC; Miele L; Xu K
Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
[TBL] [Abstract][Full Text] [Related]
16. Multi-targeting TACE/ADAM17 and gamma-secretase of notch signalling pathway in TNBC via drug repurposing approach using Lomitapide.
Sen P; Kandasamy T; Ghosh SS
Cell Signal; 2023 Feb; 102():110529. PubMed ID: 36423860
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
18. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
Wang K; Zhang Q; Li D; Ching K; Zhang C; Zheng X; Ozeck M; Shi S; Li X; Wang H; Rejto P; Christensen J; Olson P
Clin Cancer Res; 2015 Mar; 21(6):1487-96. PubMed ID: 25564152
[TBL] [Abstract][Full Text] [Related]
19. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation.
Takahashi Y; Hayashi I; Tominari Y; Rikimaru K; Morohashi Y; Kan T; Natsugari H; Fukuyama T; Tomita T; Iwatsubo T
J Biol Chem; 2003 May; 278(20):18664-70. PubMed ID: 12637581
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.
Brockwell NK; Owen KL; Zanker D; Spurling A; Rautela J; Duivenvoorden HM; Baschuk N; Caramia F; Loi S; Darcy PK; Lim E; Parker BS
Cancer Immunol Res; 2017 Oct; 5(10):871-884. PubMed ID: 28848054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
